Introduce Trilaciclib in Central Vein, Perc, New Tech 7

This code describes the administration of Trilaciclib, a myeloprotective agent, directly into a central vein. The procedure is performed percutaneously, meaning through the skin, typically using a catheter inserted into a large vein such as the subclavian, jugular, or femoral vein. This method ensures rapid and systemic delivery of the medication.

This code is used when Trilaciclib is administered intravenously via a central line to patients undergoing chemotherapy. It specifically applies to the prophylactic use of Trilaciclib to reduce the incidence of chemotherapy-induced myelosuppression, particularly in patients with extensive-stage small cell lung cancer.

• Ensure documentation clearly specifies Trilaciclib as the substance introduced.
• Verify the approach is percutaneous and the target is a central vein.
• This code is for the introduction of the substance itself, not the insertion of the central venous catheter.